BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 25556084)

  • 1. Re: 'Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
    Spanos K; Giannoukas AD
    Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353. PubMed ID: 25556084
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to 'Re: Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353-4. PubMed ID: 25556083
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):127. PubMed ID: 25882231
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points for Surgeons.
    Hurst KV; Lee R; Milosevic I; Handa A
    Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):126-7. PubMed ID: 25933476
    [No Abstract]   [Full Text] [Related]  

  • 5. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oral anticoagulants in the management of venous thromboembolism: a major advance?
    Sciascia S; Hunt BJ
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):487-8. PubMed ID: 25150440
    [No Abstract]   [Full Text] [Related]  

  • 7. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
    Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New oral anticoagulants for acute venous thromboembolism.
    Med Lett Drugs Ther; 2014 Jan; 56(1433):3-4. PubMed ID: 24419296
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
    Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J
    J Med Econ; 2014 Nov; 17(11):763-70. PubMed ID: 25078794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term benefits of preventing venous thromboembolic events.
    Cohen AT
    Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
    Dobesh PP; Fanikos J
    Drugs; 2014 Nov; 74(17):2015-32. PubMed ID: 25300410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target-specific oral anticoagulants: practice issues for the clinician.
    Plitt A; Giugliano RP
    Hosp Pract (1995); 2014 Aug; 42(3):48-61. PubMed ID: 25255406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New anticoagulants for the prevention of thromboembolism.
    Lepic K; Crowther M
    Curr Pharm Des; 2010; 16(31):3472-4. PubMed ID: 20858184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous thromboembolism management: where do novel anticoagulants fit?
    Spyropoulos AC; Turpie AG
    Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
    Yeh CH; Gross PL; Weitz JI
    Blood; 2014 Aug; 124(7):1020-8. PubMed ID: 24923298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ["Xa-tra-xa": opportunities and open questions about new anticoagulants].
    Beer JH
    Praxis (Bern 1994); 2011 Aug; 100(16):947. PubMed ID: 21910293
    [No Abstract]   [Full Text] [Related]  

  • 19. Newer anticoagulants for the prevention of venous thromboembolism.
    Jaggia A
    Natl Med J India; 2012; 25(1):22-5. PubMed ID: 22680317
    [No Abstract]   [Full Text] [Related]  

  • 20. [Introduction].
    Valle Bernad R
    Rev Clin Esp; 2012 Jan; 212 Suppl 1():1-2. PubMed ID: 23117645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.